Avelumab With Laser Interstitial Therapy for Recurrent Glioblastoma

Inclusion Criteria: * Patients must have histologically proven GBM from the initial resection. * Patients must have a life expectancy \> 16 weeks. Patients must have a Karnofsky performance status of ≥ 60 or ECOG 0 - 2 * Patient's requirement for dexamethasone should be ≤ 4mg daily or a stable dose at enrollment. * Patients must have adequate bone marrow, hepatic and renal function and hemoglobin and the test musts be performed within 14 days prior to study Day 1. * Highly effective contraception for both male and female subjects if the risk of conception exists. Exclusion Criteria: * Known history of autoimmune disorder except diabetes mellitus type 1, vitiligo or hypothyroidism only requiring hormone replacement * Patients who have received any other therapeutic investigational agent within 30 days of enrollment with the exception of the personalized MTA vaccine (NCT03223103) that can be continued throughout the study. * Patients who have received any other therapeutic investigational agent within 30 days of enrollment or prior * Prior placement of intracavitary BCNU-impregnated wafers (Gliadel). * Prior treatment with checkpoint inhibitors, CTL-4 antibody or other immunotherapy agents * Presence of any other active malignancy or prior history of malignancy, except for: basal cell carcinoma of the skin, cervical carcinoma in situ, early stage prostate carcinoma not requiring active treatment. * Prior organ transplantation, including allogeneic stem cell transplantation * Significant acute or chronic infections including, among others: HIV, AIDS, HBV * Pregnancy or lactation Contact site for full inclusion/exclusion list.